Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

No Role for Adjuvant Sorafenib or Sunitinib in Locally Advanced Kidney Cancer

TON May 2015 Vol 8 No 3 - Genitourinary Cancers
Phoebe Starr

Use of adjuvant sorafenib and sunitinib failed to extend disease-free survival (DFS) in patients with locally advanced kidney cancer at high risk of recurrence, according to initial results from the ASSURE study presented at the 2015 Genitourinary Cancers Symposium. ASSURE is the first and largest study of adjuvant vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors in kidney cancer.

Both sorafenib and sunitinib are widely effective in metastatic kidney cancer, and the investigators of ASSURE hoped that the drugs would also provide benefit in the adjuvant setting. However, the findings of this randomized trial suggest that close observation should remain the standard of care, they said.

“No one could be more disappointed in these results than me, except for patients with kidney cancer. Even though these drugs provide benefit in the metastatic setting, they did not reduce disease recurrence in the adjuvant setting, while they did increase side effects,” said lead author Naomi B. Haas, MD, Abramson Cancer Center of the University of Pennsylvania, Philadelphia.

Haas said analysis of tumor specimens collected during the trial may provide some clues to whether specific subsets of patients might derive a treatment benefit from adjuvant sorafenib or sunitinib.

Study Details


ASSURE enrolled 1943 patients who underwent complete resection and were categorized as intermediate risk or high risk for recurrence according to tumor size and grade and lymph node involvement. Treatment arms were well balanced for type of kidney cancer, type of surgery, performance status, and risk of recurrence.

Patients were randomized in a 1:1:1 ratio to receive sorafenib (n=649), sunitinib (n=647), or placebo (n=647) for 1 year. After 1322 patients were accrued, the starting doses of active drugs were lowered and titrated according to side effects, which reduced the rates of discontinuation in the experimental arms from about 26% for patients initiated at full doses to 14% for those started on reduced doses. Haas said that the dosing adjustments could have relevance for reducing discontinuation of these drugs in other settings.

Interim analysis revealed similar rates of recurrence in all 3 groups (around 40%) and of DFS (5.6-5.7 years), the primary end point of the trial. Five-year DFS rates were 53.8% for sunitinib and 52.8% for sorafenib, which were similar to the 55.8% seen in the placebo arm. Overall survival was not significantly different between treatment arms and ranged from 77% to 81%.

Based on these interim findings, the Data Safety and Monitoring Committee recommended release of the results.

Both active drugs had side effects. The most common grade ≥3 side effects were hypertension (16% for both sorafenib and sunitinib, and 4% for placebo), hand-foot reaction (sorafenib 33%, sunitinib 14%, and placebo 1%), rash (15%, 2%, and 1%, respectively), and fatigue (7%, 17%, and 3%, respectively).

Final analysis of recurrence and survival will be presented in the future.

“The findings suggest that patients with locally advanced kidney cancer treated with surgery should not receive adjuvant sorafenib or sunitinib,” Haas noted.

All patients in the trial exceeded the 4.6-year DFS projected in the null hypothesis when the trial was designed, she added.

Other adjuvant trials are ongoing in kidney cancer. These include a study of axitinib (a VEGF receptor inhibitor) and a study of everolimus (mTOR inhibitor), both of which are accruing patients. Adjuvant trials of immunotherapy and other targeted approaches are being considered.

During a question-and-answer session following Haas’ presentation at a premeeting presscast, moderator Charles Ryan, MD, professor, University of California San Francisco School of Medicine, noted that some oncologists are using adjuvant VEGF therapy with no supportive evidence. In his view, the interim results of ASSURE provide convincing evidence against this practice.

“The fact that this is a negative trial in no way diminishes its importance. Tyrosine kinase inhibitors may not be as effective as chemotherapy in the adjuvant treatment of solid tumors,” Ryan stated. “This study supports my current practice of not using these drugs in the adjuvant setting.”

Reference


Haas NB, Manola J, Uzzo RG, et al. Initial results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. J Clin Oncol. 2015;33(suppl 7):abstract 403. Presented at: 2015 Genitourinary Cancers Symposium; February 26-28, 2015; Orlando, FL.

Related Items
Adjuvant Abemaciclib plus Endocrine Therapy Game-Changer in High-Risk, HR-Positive, HER2-Negative Early Breast Cancer
Phoebe Starr
Web Exclusives published on November 3, 2020 in ESMO 2020
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
Web Exclusives published on August 17, 2020 in AACR Highlights
Why Is COVID-19 More Aggressive in Certain Patients with Cancer?
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
ctDNA May Be a Biomarker for Postsurgery MRD Positivity and Relapse in Patients with NSCLC
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
Two Ways to Target Tumors with KRAS Mutations
Phoebe Starr
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in AACR Highlights
First-in-Class Oral MK-6482 Shows Exciting Results in Clear-Cell Renal-Cell Carcinoma
Phoebe Starr
TON - June 2020, Vol 13, No 3 published on June 16, 2020 in Renal-Cell Carcinoma
Sitravatinib, Novel TKI, plus Nivolumab Elicits Good Responses in Renal-Cell Carcinoma
Phoebe Starr
TON - June 2020, Vol 13, No 3 published on June 16, 2020 in Renal-Cell Carcinoma
I-SPY 2: Durvalumab plus Olaparib and Paclitaxel Triplet in High-Risk Breast Cancer “Graduates” to Phase 3 Study
Phoebe Starr
TON - June 2020, Vol 13, No 3 published on June 16, 2020 in AACR Highlights, Breast Cancer
Atezolizumab, Vemurafenib, and Cobimetinib Triplet Therapy Improves PFS in BRAF-Positive Melanoma
Phoebe Starr
TON - June 2020, Vol 13, No 3 published on June 16, 2020 in AACR News
Last modified: April 27, 2020